Abstract
One of the most successful events in the control of infectious diseases has been the development of inactivated and oral poliovaccines in the 1950’s. The intensive use of vaccines in some areas of the world, like North America and Europe, has resulted in the disappearance of outbreaks of disease while, in many developing countries, poliomyelitis is still a major public health problem. However, this considerable accomplishment was achieved at a time when we had very little basic knowledge of poliovirus biology. This situation has changed dramatically within the last years, because, thanks to progress in molecular biology and immunochemistry, powerful new tools have become available. This has also created a favourable climate for improving the safety and the efficacy of currently used poliovaccines and for replacing them with a new one which is scientifically better designed. Nonetheless, in the near future the most predictable consequence of contemporary research on poliovirus will be the scientific explanation for poliovaccine efficacy which is still an enigmatic problem. This is the reason why poliovirus antigenicity and virulence has became an important field of investigation in the recent years. Beyond the problem of poliovaccine efficacy, the present studies on poliovirus also have an important cognitive aspect. The simplicity of the structure of poliovirion should allow elucidation of relationships between chemical structure of the genotype and biological functions of the phenotype.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Almond, J.W., 1987, The attenuation of poliovirus neurovirulence, Ann. Rev. Microbiol., 41:153.
Blondel, B., Crainic, R., and Horodniceanu, F., 1982, Le polypeptide structural VP1 du poliovirus induit des anticorps neutralisants, C. r. hebd. Séanc. Acad. Sci., Paris, 294:91.
Blondel, B., Akacem, O., Crainic, R., Couillin, P., and Horodniceanu,F., 1983, Detection by monoclonal antibodies of an antigenic determinant critical for poliovirus neutralization present on VP1 and on heat-inactivated virion, Virology, 126:707.
Blondel, B., Crainic, C. , Fichot, O., Dufraisse, G., Candrea, A., Diamond, D., Girard, M., and Horaud, F., 1986, Mutations conferring resistance to neutralization with monoclonal antibodies in type 1 poliovirus can be located outside or inside the antibody-binding site, J. of Virol., 57:81.
Emini, A., Kao, S.Y., Lewis, A.J., Wimmer, E., and Crainic, R., 1983, The functional basis of poliovirus neutralization determined with monospecific neutralizing antibodies, J. Virol., 46:466.
Fricks, C.E., Icenogle, J.P., and Hogle, J.M., 1985, Trypsin sensitivity of the Sabin strain of type 1 poliovirus : cleavage sites in virions and related particles, J. Virol. 54:856.
Hogle, M.J., Chow, M., and Filman, J.D., 1985, Three-dimensional structure of poliovirus at 2.9 A resolution, Science, 229:1.
Horaud, F., Crainic, R., Van der Werf, S., Blondel, B., Wychowski, C, Akacem, U., Bruneau, P., Couillin, P., Siffert, U., and Girard, M., 1987, Identification and characterization of a continuous neutralization epitope (C3) present on type 1 poliovirus, Prog. Med. Virol., 34:129.
Kohara, M., Abe, S., Komatsu, T., Tago, K., Arita, M, and Nomoto, A., 1988, A recombinant virus between the Sabin 1 and Sabin 3 vaccine strains of poliovirus as a possible candidate for a new type 3 poliovirus live vaccine strain, J. Virol., 62:2828.
Kuhn, R.J., Tada, H. , Ypma-Wong, M.F., Dunn, J.J., Semler, B., and Wimmer, E. , 1987, Construction of a “mutagenesis cartridge”, for poliovirus genome-linked viral protein : Isolation and characterization of viable and nonviable mutants. Proc. Natl. Acad. Sci. (USA), 85:519.
La Monica, N., Kupsky, W.J., and Racaniello, V.R., 1987a, Reduced mouse neurovirulence of poliovirus Type 2 Lansing antigenic variant selected with monoclonal antibodies, Virology. 161:429.
La Monica, N., Almond, J.W., and Racaniello, V.R., 1987b, A mouse model for poliovirus neurovirulence identifies mutations that attenuate the virus for humans, J. Virol. , 61:2917.
Martin, A., Wychowski, C, Couderc, T., Crainic, R., Hogle, J., and Girard, M., 1988, Engineering a poliovirus type 2 antigenic site on a type 1 capsid results in a chimaeric virus which is neurovirulent for mice, Embo J., 7:2839.
Minor, P.D., Ferguson, M., Evans, D.M.A., Almond, J.W., and Icenogle, J.P., 1986, Antigenic structure of polioviruses of serotypes 1, 2 and 3, J. Gen. Virol. , 67:1283.
Murray, M.G., Kuhn, R.J., Avita, M., Kawamura, N., Nomoto, A., and Wimmer, E., 1988a, Poliovirus type I/type 3 antigenic hybrid virus constructed in vitro elicits type 1 and type 3 neutralizing antibodies in rabbits and monkeys, Proc. Natl. Acad. Sci. (USA). 85:3203.
Murray, M.G., Bradley, J., Yang, X.F., Wimmer, E., Moss, E.G., and Racaniello, V.R., 1988b, Poliovirus host range is determined by a short amino acid sequence in neutralization antigenic site 1, Science. 241:213.
Racaniello, V.R., 1987, Viral sequences required for neurovirulence of poliovirus, Bioassays, 5:266.
Rossman, M.G., Arnold, E., Erickson, J.W., Frankenberger, E.A., Griffith, J.P., Hecht, H.J., Johnson, J.E., Kamer, G., Luo, M., Mosser, A.G., Rueckert, R.R., Sherry, B., and Vriend, G., 1985, The structure of human common cold virus (rhinovirus 14) and its functional relationships to other picornaviruses, Nature, Lond., 317:145.
Stanway, G., Hughes, P.J., Westrop, G.D., Evans, D., Dum, G., Minor, P.D., Schild, G.C., and Almond, J.W., 1986, Construction of poliovirus intertypic recombinants by use of cDNA, J. Virol, 57:1187.
Svehag, S.E., and Mandel, B., 1964, The formation and properties of poliovirus neutralizing antibody. I. 19s and 7s antibody formation. Differences in kinetics and antigen dose requirement for induction, J. Exp. Med., 119:1.
Van der Werf, S., Wychowski, C, Bruneau, P., Blondel, B., Crainic, R., Horodniceanu, F., and Girard, M., 1983, Localization of a poliovirus type 1 neutralization epitope in viral capsid polypeptide VP1, Proc. Natl. Acad. Sci. (USA), 80:5080.
Wychowski, C, Van der Werf, S., Siffert, O., Crainic, R., Bruneau, P., and Girard, M., 1983, A poliovirus type 1 neutralization epitope is located within amino acid residues 93 to 104 of viral capsid polypeptide VP1, Embo J., 2:2019.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1989 Plenum Press, New York
About this paper
Cite this paper
Crainic, R., Couderc, T., Martin, A., Wychowski, C., Girard, M., Horaud, F. (1989). An Insight into Poliovirus Biology. In: Askonas, B.A., Moss, B., Torrigiani, G., Gorini, S. (eds) The Immune Response to Viral Infections. Advances in Experimental Medicine and Biology, vol 257. Springer, Boston, MA. https://doi.org/10.1007/978-1-4684-5712-4_8
Download citation
DOI: https://doi.org/10.1007/978-1-4684-5712-4_8
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4684-5714-8
Online ISBN: 978-1-4684-5712-4
eBook Packages: Springer Book Archive